Cargando…

Cystic fibrosis revisited

Detalles Bibliográficos
Autores principales:	Kulkarni, H, Kansra, S, Karande, S
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer - Medknow 2019
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6813676/ https://www.ncbi.nlm.nih.gov/pubmed/31169132 http://dx.doi.org/10.4103/jpgm.JPGM_263_18

Ejemplares similares

Revisiting the Role of Leukocytes in Cystic Fibrosis
por: Averna, Monica, et al.
Publicado: (2021)

Early Antibiotics in Cystic Fibrosis: Lessons from the Cystic Fibrosis Pig Model
por: Lu, Shiping, et al.
Publicado: (2021)

Cystic Fibrosis Screen Positive, Inconclusive Diagnosis Genotypes in the Cystic Fibrosis Registry
por: Thompson, Cassandra, et al.
Publicado: (2023)

Clinical Advances in Cystic Fibrosis
por: Imperlini, Esther, et al.
Publicado: (2022)

Cystic Fibrosis: “Ionocyte Modulators”?
por: Shah, Viral S., et al.
Publicado: (2023)

The treatment burden of cystic fibrosis: a day-to-day experience with treatment as someone with cystic fibrosis
por: Maetz, Jessica, et al.
Publicado: (2021)

A New Era for Cystic Fibrosis and Cystic Fibrosis Transmembrane Conductance Regulator Modulator Trials in Infants
por: Wainwright, Claire E.
Publicado: (2022)

Cystic fibrosis in Brazil: achievements in survival
por: Vendrusculo, Fernanda Maria, et al.
Publicado: (2021)

The Impact of COVID-19 in Cystic Fibrosis
por: Flume, Patrick A., et al.
Publicado: (2022)

Evidence for Early Cystic Fibrosis Transmembrane Conductance Regulator Modulator Treatment for Children with Cystic Fibrosis Keeps Growing
por: Hoppe, Jordana E., et al.
Publicado: (2022)

Cystic Fibrosis Inflammation: Hyperinflammatory, Hypoinflammatory, or Both?
por: Murphy, Sean V., et al.
Publicado: (2019)

Dornase alpha use in patients with cystic fibrosis
por: Marostica, Paulo José C.
Publicado: (2013)

New Developments in Cystic Fibrosis Airway Inflammation
por: Palaniyar, Nades, et al.
Publicado: (2015)

Ciprofloxacin dry powder inhaler in cystic fibrosis
por: Elborn, J Stuart
Publicado: (2016)

Comparing cystic fibrosis outcomes across the pond
por: Taylor-Robinson, David C, et al.
Publicado: (2015)

Steps toward Cell Therapy for Cystic Fibrosis
por: Koh, Kyung Duk, et al.
Publicado: (2020)

Cystic fibrosis-related diabetes: The unmet need
por: Pozo, Leonardo, et al.
Publicado: (2020)

Preclinical Modeling for Therapeutic Development in Cystic Fibrosis
por: Bonfield, Tracey L.
Publicado: (2020)

Where Is the Cystic Fibrosis Transmembrane Conductance Regulator?
por: Barbry, Pascal, et al.
Publicado: (2021)

With newer tools for gene editing, is it time to revisit genetic therapy for cystic fibrosis?
por: Gupta, Anuj, et al.
Publicado: (2020)

Revisiting Host-Pathogen Interactions in Cystic Fibrosis Lungs in the Era of CFTR Modulators
por: Ribeiro, Carla M. P., et al.
Publicado: (2023)

Shifting Landscape of Airway Infection in Early Cystic Fibrosis
por: Hoppe, Jordana E., et al.
Publicado: (2019)

Nutrition in Cystic Fibrosis: as important as the management of pulmonary disease
por: Adde, Fabíola Villac
Publicado: (2015)

Airway Inflammatory/Immune Responses in COPD and Cystic Fibrosis
por: De Rose, Virginia, et al.
Publicado: (2018)

Editorial: Special Issue on “Therapeutic Approaches for Cystic Fibrosis”
por: Pedemonte, Nicoletta
Publicado: (2020)

Is PI3K a Villain in Cystic Fibrosis?
por: Natarajan, Viswanathan
Publicado: (2020)

The Future of Highly Effective Modulator Therapy in Cystic Fibrosis
por: Daines, Cori L., et al.
Publicado: (2021)

Infection and Inflammation MUC up the Cystic Fibrosis Airway
por: Ma, Jonathan
Publicado: (2022)

Microbial Metabolites in Cystic Fibrosis: A Target for Future Therapy?
por: Widder, Stefanie, et al.
Publicado: (2019)

Staphylococcus aureus in cystic fibrosis: problem bug or an innocent bystander?
por: Hurley, Matthew N.
Publicado: (2018)

Why Do We Screen Newborn Infants for Cystic Fibrosis?
por: Barben, Jürg, et al.
Publicado: (2020)

Combination Therapy with Lumacaftor–Ivacaftor in Cystic Fibrosis. Keeping It Real
por: Sala, Marc A., et al.
Publicado: (2020)

Early Aspergillosis in Cystic Fibrosis and Air Trapping: Guilt by Association?
por: Nichols, Dave P., et al.
Publicado: (2020)

Airway Surface Liquid and Impaired Antiviral Defense in Cystic Fibrosis
por: Voynow, Judith A., et al.
Publicado: (2020)

Gain-of-Function Polymorphisms in Human Inflammasomes: Implications for Cystic Fibrosis
por: Jeansonne, Duane, et al.
Publicado: (2021)

Towards a new definition of non-cystic fibrosis bronchiectasis
por: Martinez-Garcia, Miguel Ángel, et al.
Publicado: (2022)

The Need for Precision Therapies as Determined by Genetic Signature for Cystic Fibrosis
por: Zahir, Farah R.
Publicado: (2021)

Modulator treatment for people with cystic fibrosis: moving in the right direction
por: Elborn, J. Stuart
Publicado: (2020)

Immune Response in Cystic Fibrosis: Interplay between the Host and Microbes
por: Boutin, Sébastien, et al.
Publicado: (2023)

HALTing Nontuberculous Mycobacteria in Cystic Fibrosis Centers: Is There Something in the Water?
por: Olivier, Kenneth N., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ctqil0s0krns48bp4gnjd4v8qd